Key Details
Price
$132.81Annual ROE
-18.81%Beta
1.05Events Calendar
Next earnings date:
Feb 06, 2025Recent quarterly earnings:
Nov 04, 2024Recent annual earnings:
Feb 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 25, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Illumina (ILMN) has the right mix of factors that could lead to a strong earnings report in its next announcement. Be ready for the important expectations.
Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
Our Zacks Earnings ESP makes it simpler to identify stocks that are likely to exceed quarterly earnings predictions.
Illumina (ILMN) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.
Illumina, Inc. (NASDAQ:ILMN) will hold its 43rd Annual JPMorgan Healthcare Conference Call on January 14, 2025, at 12:00 PM ET. The company will be represented by Jacob Thaysen, the Chief Executive Officer, and Ankur Dhingra, the Chief Financial Officer. Rachel Vatnsdal from JPMorgan will also be participating in the call.
Illumina is partnering with NVIDIA to enhance technology for analyzing multiomic data, which will speed up clinical research, genomics AI, and drug discovery. This collaboration will merge Illumina's sequencing technologies and software with NVIDIA's tools to improve the analysis of large datasets. Together, they aim to leverage AI advancements to better handle the complexities of multiomic research.
On Monday, Truveta, a company focused on medical data research, announced that Regeneron Pharmaceuticals, Illumina, and 17 health systems in the U.S. will invest $320 million in the company. This investment is part of a plan to create the largest genetic database in the world.
Illumina, Inc. has launched a pilot program to study 50,000 samples from the UK Biobank, working with partners like deCODE Genetics and GSK. This program will use Illumina's new proteomics assay, Illumina Protein Prep™, which utilizes SOMAmer® technology to enhance access to proteomic information. The goal is to create an important reference data set for future research.
SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced that it will release its fourth quarter and full year 2024 results after the market closes on Thursday, February 6, 2025. On that day, at 1:30 pm Pacific Time (4:30 pm Eastern Time), CEO Jacob Thaysen, PhD, and CFO Ankur Dhingra will hold a conference call to discuss the financial and operational results with analysts, investors, and others.
Illumina, Inc. has introduced updates to its NovaSeq X Series, including a new single-flow-cell system and advanced software, along with new kits. The NovaSeq X Sequencing System provides the same high-quality flow cells and speed as the NovaSeq X Plus, but at a more affordable price for labs with lower sequencing needs. This launch enhances multiomic capabilities and supports the recently released Illumina Single-Cell Prep.
FAQ
- What is the primary business of Illumina?
- What is the ticker symbol for Illumina?
- Does Illumina pay dividends?
- What sector is Illumina in?
- What industry is Illumina in?
- What country is Illumina based in?
- When did Illumina go public?
- Is Illumina in the S&P 500?
- Is Illumina in the NASDAQ 100?
- Is Illumina in the Dow Jones?
- When was Illumina's last earnings report?
- When does Illumina report earnings?
- Should I buy Illumina stock now?